Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

ARNA 4.23 -0.09 (-2.08%)
price chart
A Realistic View Of Belviq In The Short Term
Over my 10-year career trading biotechs, I have found that retail investors are all too often unrealistic about new therapies and the subsequent appreciation of a company's common stock. The retail crowd surrounding ARNA appears to be repeating this ...
Related articles »  
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Related articles »  
Vivus Or Arena: Who Has The Edge?
Two of the three major players in the treatment of obesity, VIVUS Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals Inc. (NASDAQ:ARNA) released their financial results and provided an update on recent developments.
Related articles »  
CEO of the Year, Final Round: Arena Pharmaceuticals vs. Lumber Liquidators
On one hand we have Jack Lief of Arena Pharmaceuticals, who led his company to develop Belviq, the anti-obesity drug recently approved by the FDA that's currently in the driver's seat to be the first fat-busting drug approved internationally (all ...
Acadia Pharma Rockets Higher on Study Results
However, the stock gave up much of its gains in the second half of the year, as weak sales pressured the company. Still, year-to-date, shares are up over 17 percent.
Related articles »  
Arena Pharma Sinks Under Weight Of Vivus' Troubles
Despite having split economics on Belviq, ARNA now trades at a substantial premium to VVUS. The most worrisome disclosure by Vivus Tuesday was the fact that 30% of patients willing to try Qsymia and who get actually get a prescription from their doctor ...
Related articles »  
Vivus, Arena shares jump on insurance coverage for diet pills
N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up.
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Related articles »  
Indian board rejects AstraZeneca's patent plea on cancer drug
Natco and another domestic drugmaker, G. M. Pharma, had opposed the initial patent application for AstraZeneca quinazoline derivative.
Related articles »  
Where to Get Job Training to Boost Resume
Jannette Karaff, business service representative for the West Central Arkansas Career Development Center System Inc., agrees.
Five Smart Moves a First-Time Buyer Should Consider
As a first-time real estate buyer, you probably have no idea how the overall purchasing process works or how to make sure you're making a smart decision to purchase.